William R. Sellers

85.3k citations

165 papers · 34.8k indexed · 19 hit papers · h-index 82

Molecular Biology top 0.05%
Oncology top 0.05%
Pulmonary and Respiratory Medicine top 0.05%
Cancer Research top 0.05%
Genetics top 0.5%

Co-authors: Matthew Meyerson Francisca Vázquez Heidi Greulich William G. Kaelin Pasi A. Jänne Massimo Loda Frederic J. Kaye J. Guillermo Paez
Topics: PI3K/AKT/mTOR signaling in cancer (29 papers)Cancer-related Molecular Pathways (29 papers)Cancer Genomics and Diagnostics (16 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature Science Cell
Partner nations: United States Switzerland Germany

In The Last Decade

William R. Sellers

157 papers receiving 34.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →
Gene expression correlates of clinical prostate cancer behavior

2002 1.8k citations Phillip G. Febbo, Massimo Loda et al. profile →
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

2005 1.1k citations Levi A. Garraway, Hans R. Widlund et al. profile →
Molecular characterization of the tumor microenvironment in breast cancer

2004 1.0k citations Rameen Beroukhim, Dale Porter et al. profile →
BRAF mutation predicts sensitivity to MEK inhibition

2005 1.0k citations David B. Solit, Levi A. Garraway et al. profile →
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

2008 954 citations Sauveur-Michel Maira, Frédéric Stauffer et al. Molecular Cancer Therapeutics profile →
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

2004 781 citations Pradip K. Majumder, Phillip G. Febbo et al. profile →
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties

1992 777 citations William G. Kaelin, William R. Sellers et al. profile →
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

2004 725 citations William R. Sellers et al. profile →
Phosphorylation of the PTEN Tail Regulates Protein Stability and Function

2000 662 citations Francisca Vázquez, William R. Sellers et al. profile →
Quantitative Proteomics of the Cancer Cell Line Encyclopedia

2020 574 citations Judit Jané‐Valbuena, Dale Porter et al. profile →
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

2013 539 citations William R. Sellers, Nancy Pryer et al. profile →
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

2005 536 citations Heidi Greulich, Pasi A. Jänne et al. profile →
Interaction between the retinoblastoma protein and the oncoprotein MDM2

1995 512 citations William R. Sellers et al. profile →
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

1999 500 citations Massimo Loda, William R. Sellers et al. profile →
TSC2 regulates VEGF through mTOR-dependent and -independent pathways

2003 429 citations Francisca Vázquez, William R. Sellers et al. profile →
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

2013 425 citations Manav Korpal, Joshua M. Korn et al. Cancer Discovery profile →
Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors

1996 323 citations William R. Sellers, William G. Kaelin et al. profile →
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

2009 310 citations Rameen Beroukhim, Arianna Di Napoli et al. Cancer Research profile →

Peers

Countries citing papers authored by William R. Sellers

Since Specialization

Citations

This map shows the geographic impact of William R. Sellers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William R. Sellers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William R. Sellers more than expected).

Fields of papers citing papers by William R. Sellers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William R. Sellers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William R. Sellers. The network helps show where William R. Sellers may publish in the future.

Co-authorship network of co-authors of William R. Sellers

This figure shows the co-authorship network connecting the top 25 collaborators of William R. Sellers. A scholar is included among the top collaborators of William R. Sellers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William R. Sellers. William R. Sellers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation 2019 ·Clinical Cancer Research ·Sabrina Baltschukat,Barbara Schacher Engstler,Alan Huang,Huai-Xiang Hao,Angela Tam,Hui Qin Wang,Jinsheng Liang,Matthew T. DiMare,Hyo-Eun Carrie Bhang,Youzhen Wang,Pascal Furet,William R. Sellers,Francesco Hofmann,Joseph Schoepfer,Ralph Tiedt	105
2	Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling 2014 ·Cancer Research ·Marie Schoumacher,Kristen E. Hurov,Joseph Lehár,Yan Yan‐Neale,Yuji Mishina,Dmitriy Sonkin,Joshua M. Korn,Daisy Flemming,Michael D. Jones,Brandon Antonakos,Vesselina G. Cooke,(unknown),(unknown),Mark Stump,William R. Sellers,Nika N. Danial,Wenlin Shao	28
3	An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)breakdown → 2013 ·Cancer Discovery ·Manav Korpal,Joshua M. Korn,Xueliang Gao,Daniel P. Rakiec,David A. Ruddy,Shivang Doshi,Jing Yuan,Steve G. Kovats,Sunkyu Kim,Vesselina G. Cooke,John E. Monahan,Frank Stegmeier,Thomas M. Roberts,William R. Sellers,Wenlai Zhou,Ping Zhu	425
4	The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo 2012 ·Molecular Cancer Therapeutics ·Daniel L. Menezes,Pietro Taverna,Michael Rugaard Jensen,Tinya J. Abrams,Darrin D. Stuart,Guoying Karen Yu,David M. Duhl,Timothy Machajewski,William R. Sellers,Nancy Pryer,Zhenhai Gao	57
5	A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients 2011 ·Cancer Research ·Ralph Tiedt,(unknown),Pascal Furet,B.A. Appleton,(unknown),Joseph Schoepfer,Emily Buck,David A. Ruddy,John E. Monahan,Michael D. Jones,Jutta Blank,Dorothea Haasen,Peter Drueckes,Markus Wartmann,Clive McCarthy,William R. Sellers,Francesco Hofmann	99
6	An Oncogenic Role for ETV1 in Melanoma 2010 ·Cancer Research ·Judit Jané‐Valbuena,Hans R. Widlund,Sven Perner,Laura A. Johnson,(unknown),William M. Lin,Alissa C. Baker,Rosalynn M. Nazarian,Krishna G. Vijayendran,William R. Sellers,William C. Hahn,Lyn M. Duncan,Mark A. Rubin,David E. Fisher,Levi A. Garraway	81
7	The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells 2010 ·Cancer Research ·Zainab Jagani,Dmitri Wiederschain,Alice Loo,Dan He,Rebecca Mosher,Paul Fordjour,John E. Monahan,Michael Morrissey,(unknown),Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch	48
8	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidneybreakdown → 2009 ·Cancer Research ·Rameen Beroukhim,(unknown),Arianna Di Napoli,Kirsten D. Mertz,Apryle Seeley,Maira M. Pires,David Linhart,Robert Worrell,Holger Moch,Mark A. Rubin,William R. Sellers,Matthew Meyerson,W. Marston Linehan,William G. Kaelin,Sabina Signoretti	310
9	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers 2009 ·Cancer Research ·Susan Wee,Zainab Jagani,Kay X. Xiang,Alice Loo,Marion Dorsch,Yung‐Mae Yao,William R. Sellers,Christoph Lengauer,Frank Stegmeier	354
10	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel 2008 ·Cancer Research ·Ayana Sawai,Sarat Chandarlapaty,Heidi Greulich,Mithat Gönen,Qing Ye,Carlos L. Arteaga,William R. Sellers,Neal Rosen,David B. Solit	145
11	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitybreakdown → 2008 ·Molecular Cancer Therapeutics ·Sauveur-Michel Maira,Frédéric Stauffer,Josef Brueggen,Pascal Furet,Christian Schnell,Christine Fritsch,Saskia M. Brachmann,Patrick Chêne,Alain De Pover,(unknown),Doriano Fabbro,Daniela Gabriel,Marjo Simonen,Leon O. Murphy,Peter M. Finan,William R. Sellers,Carlos García-Echeverría	954
12	A Smac Mimetic Rescue Screen Reveals Roles for Inhibitor of Apoptosis Proteins in Tumor Necrosis Factor-α Signaling 2007 ·Cancer Research ·Alex Gaither,Dale Porter,Yao Yao,Jason Borawski,Guang Yang,Jerry Donovan,David R. Sage,Joanna Slisz,Mary Tran,Christopher Straub,(unknown),Vadim Iourgenko,Alan Huang,Yan Chen,Robert Schlegel,Mark Labow,Stephen E. Fawell,William R. Sellers,Leigh Zawel	178
13	Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane 2006 ·Proceedings of the National Academy of Sciences ·Francisca Vázquez,Satomi Matsuoka,William R. Sellers,Toshio Yanagida,Masahiro Ueda,Peter N. Devreotes	155
14	Signal Transducer and Activator of Transcription 3 Is Required for the Oncogenic Effects of Non–Small-Cell Lung Cancer–Associated Mutations of the Epidermal Growth Factor Receptor 2006 ·Cancer Research ·James V. Alvarez,Heidi Greulich,William R. Sellers,Matthew Meyerson,David A. Frank	206
15	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer 2006 ·Cancer Research ·Sven Perner,Francesca Demichelis,Rameen Beroukhim,Folke Schmidt,Juan Miguel Mosquera,Sunita R. Setlur,Joëlle Tchinda,Scott A. Tomlins,Matthias D. Hofer,Kenneth J. Pienta,Rainer Kuefer,Robert L. Vessella,Xiao Sun,Matthew Meyerson,Charles Lee,William R. Sellers,Arul M. Chinnaiyan,Mark A. Rubin	388
16	p63 regulates commitment to the prostate cell lineage 2005 ·Proceedings of the National Academy of Sciences ·Sabina Signoretti,Maira M. Pires,(unknown),James W. Horner,Chiara Grisanzio,(unknown),Pradip K. Majumder,Frank McKeon,Philip W. Kantoff,William R. Sellers,Massimo Loda	121
17	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis 2005 ·Cancer Research ·Xiaojun Zhao,Barbara A. Weir,Thomas LaFramboise,Ming Gang Lin,Rameen Beroukhim,Levi A. Garraway,Javad Beheshti,Jeffrey C. Lee,Katsuhiko Naoki,William G. Richards,David J. Sugarbaker,Fei Chen,Mark A. Rubin,Pasi A. Jänne,Luc Girard,John D. Minna,David C. Christiani,Cheng Li,William R. Sellers,Matthew Meyerson	242
18	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapybreakdown → 2004 ·Science ·J. Guillermo Paez,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumi Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,Bruce E. Johnson,Matthew Meyerson	7539
19	An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays 2004 ·Cancer Research ·Xiaojun Zhao,Cheng Li,J. Guillermo Paez,Koei Chin,Pasi A. Jänne,(unknown),Luc Girard,John D. Minna,David C. Christiani,Chris Leo,Joe W. Gray,William R. Sellers,Matthew Meyerson	401
20	Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells 2004 ·Cancer Research ·Raanan Berger,Phillip G. Febbo,Pradip K. Majumder,Jean J. Zhao,Sayan Mukherjee,Sabina Signoretti,Katrina Campbell,William R. Sellers,Thomas M. Roberts,Massimo Loda,Todd R. Golub,William C. Hahn	140

About William R. Sellers

William R. Sellers is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 165 papers that have together received 34.8k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (29 papers), Cancer-related Molecular Pathways (29 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (13.6k citations), Cancer Research (7.1k citations) and Molecular Biology (22.7k citations). William R. Sellers has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Matthew Meyerson, Francisca Vázquez, Heidi Greulich, William G. Kaelin, Pasi A. Jänne, Massimo Loda, Frederic J. Kaye, J. Guillermo Paez, Jeffrey C. Lee and Noriaki Nakamura. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact